The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Intensity of18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin’s Lymphoma
Abstract
Purpose: 18 Fluorodeoxyglucose positron emission tomography (FDG PET) is widely used for the staging of lymphoma. We investigated whether the intensity of tumor FDG uptake could differentiate between indolent and aggressive disease. Materials and Methods: PET studies of 97 patients with non-Hodgkin's lymphoma who were untreated or had relapsed and/or persistent disease and had not received treatment within the last 6 months were analyzed, and the highest standardized uptake value (SUV) per study was recorded. Correlations were made with histopathology. Results: FDG uptake was lower in indolent than in aggressive lymphoma for patients with new (SUV, 7.0 ± 3.1 v 19.6 ± 9.3; P < .01) and relapsed (SUV, 6.3 ± 2.7 v 18.1 ± 10.9; P = .04) disease. Despite overlap between indolent and aggressive disease in the low SUV range (indolent, 2.3 to 13.0; aggressive, 3.2 to 43.0), all cases of indolent lymphoma had an SUV ≤ 13. A receiver operating characteristic (ROC) analysis demonstrated that the SUV distinguished reasonably well between aggressive and indolent disease (area under ROC curve, 84.7%), and an SUV > 10 excluded indolent lymphoma with a specificity of 81%. With a higher cutoff for the SUV, the specificity would have been higher. Conclusion: FDG uptake is lower in indolent than in aggressive lymphoma. Patients with NHL and SUV > 10 have a high likelihood for aggressive disease. This information may be helpful if there is discordance between biopsy and clinical behavior.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K., Vardiman, J., Lister, T. A., & Bloomfield, C. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3835 · Cited by 3,267
The Statistical Evaluation of Medical Tests for Classification and Prediction
(2005) · Technometrics · doi:10.1198/tech.2005.s278 · Cited by 1,899
Jerusalem, G., Beguin, Y., Fassotte, M. F., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (1999) · Blood · doi:10.1182/blood.v94.2.429 · Cited by 565
Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding
Erdi, Y. E., Mawlawi, O., Larson, S. M., Imbriaco, M., Yeung, H., Finn, R., & Humm, J. L. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971215)80:12+<2505::aid-cncr24>3.0.co;2-f · Cited by 480
Self-citationHuang, (. S.-C. (2000) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(00)00155-4 · Cited by 458
Vansteenkiste, J. F., Stroobants, S. G., Dupont, P. J., De Leyn, P. R., Verbeken, E. K., Deneffe, G. J., Mortelmans, L. A., & Demedts, M. G. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3201 · Cited by 439
Utility of FDG-PET scanning in lymphoma by WHO classification
Elstrom, R., Guan, L., Baker, G., Nakhoda, K., Vergilio, J.-A., Zhuang, H., Pitsilos, S., Bagg, A., Downs, L., Mehrotra, A., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2778 · Cited by 437
Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J., de Groot, T., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., & Verhoef, G. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf256 · Cited by 410
Römer, W., Hanauske, A.-R., Ziegler, S. I., Thödtmann, R., Weber, W., Fuchs, C., Enne, W., Herz, M., Nerl, C., Garbrecht, M., et al. (1998) · PubMed · doi:10.1182/blood.v91.12.4464 · Cited by 335
Ahuja, V., Coleman, R. E., Herndon, J., & Patz, E. F. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980901)83:5<918::aid-cncr17>3.0.co;2-y · Cited by 331
Cited by
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Barrington, S. F., Mikhaeel, N. G., Kostakoglu, L., Meignan, M., Hutchings, M., Müeller, S. P., Schwartz, L. H., Zucca, E., Fisher, R. I., Trotman, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5229 · Cited by 1,665
Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M., Guermazi, A., Wiseman, G. A., Kostakoglu, L., Scheidhauer, K., Buck, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2305 · Cited by 1,335
Fass, L. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.04.001 · Cited by 822
Lin, C., Itti, E., Haioun, C., Petegnief, Y., Luciani, A., Dupuis, J., Paone, G., Talbot, J.-N., Rahmouni, A., & Meignan, M. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.042093 · Cited by 394
Metadata
- Authors
- Schöder, H., Noy, A., Gönen, M., Weng, L., Green, D., Erdi, Y. E., Larson, S. M., & Yeung, H. W. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-07-20
- Volume
- 23
- Issue
- 21
- Pages
- 4643-4651
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2093967829
- Cited by
- 491
- References
- 26
- FWCI
- 17.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intensity of18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin’s Lymphoma. https://app.cochat.ai/papers/10.1200/jco.2005.12.072
- The paper
- Schöder, H., Noy, A., Gönen, M., Weng, L., Green, D., Erdi, Y. E., Larson, S. M., & Yeung, H. W. D. (2005). Intensity of18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin’s Lymphoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.12.072
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.